0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Ganciclovir Prophylaxis To Prevent Cytomegalovirus Disease after Allogeneic Marrow Transplant

James M. Goodrich, PhD, MD; Raleigh A. Bowden, MD; Lloyd Fisher, PhD; Claire Keller, BSN, RN; Gary Schoch, BA; and Joel D. Meyers†, MD
[+] Article and Author Information

From the Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, Washington. Requests for Reprints: James Goodrich, PhD, MD, The University of Texas M.D. Anderson Cancer Center, Section of Infectious Diseases (Box 47), 1515 Holcombe Boulevard, Houston, TX 77030. Acknowledgment: The authors thank Ms. Gonzalez-White and Ms. Shirley Tyler for preparation of the manuscript. Grant Support: Supported by grants CA 18029, CA 15704, and HL 36444 from the National Institutes of Health. Dr. Goodrich was supported in part by an award from the Poncin Scholarship Fund, Seattle, Washington.


Copyright ©2004 by the American College of Physicians


Ann Intern Med. 1993;118(3):173-178. doi:10.7326/0003-4819-118-3-199302010-00003
Text Size: A A A

Objective: To study the efficacy and toxicity of ganciclovir prophylaxis given at engraftment to cytomegalovirus (CMV)-seropositive, allogeneic bone marrow transplant recipients.

Design: A double-blind, placebo-controlled study.

Setting: The Fred Hutchinson Cancer Research Center, a referral marrow transplant center.

Patients: This study was conducted from November 1990 to August 1991. Ninety-three CMV-seropositive patients were entered into the study before marrow transplant, with 64 patients randomized to receive the study drug after marrow engraftment. Thirty-one patients received placebo, and 33 received ganciclovir. The dose was 5 mg/kg body weight administered intravenously twice daily for 5 days, followed by once daily until day 100 after transplant.

Measurements: Outcome variables measured were CMV infection, monitored by weekly cultures, and neutropenia, defined as an absolute neutrophil count of 0.750 × 10−9/L for 2 consecutive days. Cytomegalovirus disease and mortality were secondary end points.

Results: Fourteen (45%) placebo recipients developed CMV infection in the first 100 days after marrow transplant compared with one (3%) ganciclovir recipient (P < 0.001). Nine (29%) placebo recipients developed CMV disease compared with no cases in the ganciclovir group during the first 100 days (P < 0.001). Neutropenia occurred in 10 ganciclovir recipients (30%) compared with no cases in the placebo group during the period of observation (P = 0.001). In a separate analysis, patients on ganciclovir who became neutropenic were at greater risk (relative risk, 4.3; P = 0.02) for bacterial infection. Mortality between the two study groups did not differ statistically at 100 and 180 days.

Conclusion: Ganciclovir given prophylactically after engraftment is effective in suppressing CMV infection and disease. Neutropenia is an important side effect of ganciclovir use and is associated with an increased risk for bacterial infection.

†Deceased.

Figures

Grahic Jump Location
Figure 1.
Cytomegalovirus infection after allogeneic marrow transplant.P

Kaplan-Meier product limit estimate of the probability of infection during the first 100 days after transplantation among ganciclovir (— — —) and placebo (—) recipients. The probability of infection differed significantly between groups ( = 0.0001).

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)